FDA Identifies Cases Of Serious Liver Injury In Patients Taking Amgen's Tavneos For Severe Active Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis

The FDA has reported cases of serious liver injury in patients using Amgen's Tavneos (avacopan) for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. This development may impact the drug's market performance and raise concerns regarding its safety profile. Amgen's stock ticker is AMGN.